Health Science Reports (Jul 2024)

Clinical outcomes and considerations in outpatient with COVID‐19 receiving remdesivir therapy

  • Zeinab Siami,
  • Aziz Rasooli,
  • Jayran Zebardast,
  • Illahay Jalali,
  • Saeidreza Jamalimoghadamsiahkali

DOI
https://doi.org/10.1002/hsr2.2252
Journal volume & issue
Vol. 7, no. 7
pp. n/a – n/a

Abstract

Read online

Abstract Introduction This retrospective cross‐sectional study aimed to assess the outcomes of Covid‐19 patients who received remdesivir therapy at the outpatient department of Ziaian Hospital. Method A total of 514 eligible patients were included between May and September 2021. Covid‐19 diagnosis was confirmed through positive SARS‐COV‐2 PCR tests or chest CT scans. Due to limited hospital beds, patients received remdesivir on an outpatient basis. Results Patients received six daily doses of remdesivir for 5 days. Those referred to a physician within 7 days of symptom onset had similar hospitalization rates compared to later referrals. Lower blood saturation levels were associated with a higher likelihood of hospital admission, indicating that earlier administration of remdesivir may be more effective. Patients with over 50% lung involvement had higher rates of disease progression despite treatment. Corticosteroids did not significantly improve outcomes in patients with saturation above 90%. Discontinuation of remdesivir due to side effects was rare, with only 1% experiencing increased liver enzymes, 1.2% facial redness and tremors, and 1.5% allergies. After 1 week of treatment, patients commonly reported symptoms such as hair loss, fatigue, body pain, lethargy, and anorexia, particularly among hospitalized patients. Discussion Patients generally preferred outpatient treatment over hospitalization. Body mass index (BMI) did not significantly impact hospitalization rates, although average weight tended to be higher among inpatients. The study confirmed the effectiveness of remdesivir therapy with a low occurrence of side effects. Conclusion This retrospective study evaluated the outcomes of Covid‐19 patients receiving remdesivir at an outpatient department. Early administration of remdesivir showed better outcomes, while corticosteroids had limited benefits. Outpatient treatment was favored, and BMI did not significantly influence hospitalization rates. Remdesivir demonstrated efficacy with a low incidence of side effects.

Keywords